Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is a once-weekly injection, and that weekly interval is the clinically studied schedule. In practice, the licensed guidance allows a maximum gap of twelve days between doses before you simply skip that injection and resume on your usual day. Going beyond twelve days is not recommended, and the timing matters more than many people realise. These are prescription-only medicines that require clinical assessment before you start, and any significant deviation from your schedule is worth discussing with your prescriber rather than improvising around.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The summary answer is twelve days. If your usual injection day passes and you remember within that window, you can take the missed dose and then continue from a new weekly schedule based on that date. If more than twelve days have passed, the guidance is to leave that dose and pick up your next injection on the originally planned day, as if the missed one never happened.
This twelve-day rule exists because semaglutide has a half-life of roughly one week in the body. Once you go beyond twelve days without a dose, plasma levels have fallen enough that reintroducing the medicine behaves more like restarting than resuming. The NHS medicines page for semaglutide sets this out clearly, and the Patient Information Leaflet included with your pen gives the same instruction.
A quick habit worth building: set a recurring phone reminder for your injection day and note the date on the pen's cardboard sleeve when you open it. It takes under a minute and prevents the mental arithmetic later.
Two things tend to follow a prolonged gap. First, appetite suppression fades. Semaglutide works by activating GLP-1 receptors involved in hunger signalling and gastric emptying. Once the medicine clears, those pathways return toward their baseline, which is why people often notice hunger coming back more sharply after even a week's delay. The research behind how long a Wegovy shot's effect actually lasts gives more background on the pharmacokinetics involved.
Second, when you restart after a long break, your body may respond as though it is encountering the medicine for the first time at that dose. Nausea, stomach discomfort and other gastrointestinal effects (which typically settle during the early titration weeks) can return. This is not dangerous for most people, but it is uncomfortable and is a good reason to contact your prescriber if your gap was substantial. They may suggest stepping back a dose temporarily.
For context on how the weekly dosing fits into the longer treatment journey, how long you can take Wegovy and what shapes that decision covers duration and continuation in more detail.
No, the twelve-day maximum applies across all doses in the Wegovy schedule, from the 0.25 mg starting dose through to the 2.4 mg maintenance dose (and the newer 7.2 mg option where prescribed). What does change is the consequence. Missing a dose during early titration is generally less disruptive to weight outcomes than missing one at maintenance, because the appetite-suppressing effect is already more established at higher doses and the drop-off is more noticeable.
It is also worth noting that the advice changes slightly if you are still in the titration phase. If a prolonged gap coincides with a planned dose increase, your prescriber may want to hold the increase until you are back on a consistent schedule. That is not a setback, it is standard cautious practice. The NHS England guidance on weight-management injections reinforces the principle that clinical oversight during titration is important, not optional.
If you are thinking about what results a consistent schedule produces over time, average weight loss figures from Wegovy's clinical trials put those numbers in perspective. And if you are wondering how long treatment typically runs, how long Wegovy can be used explains the licensed duration and what continuation looks like.
Check the date of your last injection first. If it was within twelve days, take the dose now and set your new weekly day from today. If it was more than twelve days ago, skip this dose and take your next one on your original day. Write that date somewhere visible.
If you are unsure whether your gap qualifies, or if this is the second or third missed dose in a row, contact your prescriber. A brief message through your provider's aftercare channel is usually enough. At nume, our support team connects you to clinical aftercare seven days a week, so you are not left making that judgement alone.
For people still deciding whether Wegovy is the right option for them, our Wegovy overview page covers the licence, the evidence and what the treatment involves from the beginning. If you are ready to explore treatment, a free consultation with our prescribers is the straightforward next step, no commitment required, reviewed by a real clinician the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.